FDA alignment opens third dosing cohort for Perspective's 212Pb-VMT-α-NET NET trial at 6 mCi (20% higher)

Perspective Therapeutics, Inc.

FDA opened Cohort 3 at 6 mCi (20% higher than Cohort 2) per dose for patients weighing >60 kg.
No DLTs observed among 42 patients treated; no grade ≥4 AEs; anti-tumor activity in 4 of 7 Cohort 2 DLT-evaluable patients.
Dosimetry sub-study using [203Pb]VMT-α-NET presented at SNMMI 2025 shows feasibility and tolerable absorbed doses.
Company on track to submit further clinical updates in 2H 2025, including longer safety and anti-tumor activity data.

item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.